New combo therapy shows promise for Hard-to-Treat cancers
NCT ID NCT05293496
First seen Nov 01, 2025 · Last updated Jun 18, 2026 · Updated 31 times
Summary
This early-stage study tested a new drug combination (vobramitamab duocarmazine plus lorigerlimab) in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants received the drugs every 4 weeks for up to 2 years. This is not a cure, but aims to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Carolina BioOncology
Huntersville, North Carolina, 28078, United States
-
Florida Cancer Specialists and Research Institute
Sarasota, Florida, 34232, United States
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21287, United States
-
Stephenson Cancer Center, The University of Oklahoma
Oklahoma City, Oklahoma, 73104, United States
-
University of California, Los Angeles
Los Angeles, California, 90095, United States
-
University of California, San Francisco
San Francisco, California, 94115, United States
-
University of Pittsburgh Medical Center, Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232, United States
-
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia, 22908, United States
-
Weill Cornell Medicine
New York, New York, 10065, United States
-
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.